Last month Sarah Constantin reported on a new potential treatment for sepsis (a life-threatening bacterial infection of the blood), developed by Dr. Paul Marik. The good news is that the ingredients are all pretty common off-patent vitamins and medications, so if approved it will be really cheap. I haven’t researched this treatment myself, but Sarah thinks it looks promising, and Sarah Constantin is the autodidact medical researcher I want to be when I grow up (she’s also a friend of mine). To quote her:
Sepsis is a really big deal. More people die from sepsis every year than from diabetes and COPD combined. Ten thousand people die of sepsis every day. A lot of these cases are from pneumonia in elderly people, or hospital-acquired infections. Curing sepsis would put a meaningful dent in the kind of hell that hospital-bound old people experience, that Scott described in Who By Very Slow Decay.
Sepsis is the destructive form of an immune response to infection. Normally the infection is managed with antibiotics, but the immune response still kills 30% of patients. Corticosteroids, which reduce the immune response, and vitamin C, which reduces blood vessel permeability so that organs are less susceptible to pro-inflammatory signals, can treat the immune response itself.
What evidence do we have for this treatment? It’s made up of individual ingredients known or suspected to fight sepsis, and in a retrospective study, 0% of Marik’s patients died of sepsis (although 8% died from their underlying illness), compared to half in the ~control group. But a retrospective study isn’t enough; we need the gold standard, a randomized control study.
The good news is this treatment is made from very common off patent medications, so if approved it will be very cheap. The bad news is that this treatment will be really cheap, so no there’s no monetary incentive to fund an RCT. To be clear: this is not the fault of pharmaceutical companies. No one is holding something back. They are merely responding to the incentives we have set up. But if you’d like to change the incentive system we live under, the principal investigator is now attempting to crowdfund an RCT of his treatment. Donations are handled through Eastern Virginia Medical School and are tax deductible.
My budget for substantial donations for the year is still exhausted by Tostan. But contributing to a better set of incentives for medical research is worth $20 out of my symbolism budget. Better incentives here means not just that treatments can be researched even if they aren’t monetizable, but that people like Sarah have an incentive to do this research and share it.* To that end, if you do decide to donate as a result of Sarah’s post, I’d really appreciate it if you also filled out her donation form so she can see how much she raised (for bonus points note acesounderglass.com as your immediate referrer so I can see how much I raised).
*”People like Sarah” technically includes me, since this is almost exactly the reasoning Ozy Brennan gave for donating to my favorite charity, Tostan.